Myovant, Sumitomo Beat Investor Suit Over Skadden Advice

By Katryna Perera · January 2, 2024, 10:22 PM EST

Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher &...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Zappia v. Myovant Sciences Ltd. et al

Case Number

1:23-cv-08097

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

September 13, 2023